Search research articles
Contact Us
Filters
Showing results (11-20 of 105) with videos related to
Page
of 11
Sort By:
The New England Journal of Medicine
|
January 5, 1995
The use of placebo controls
J J Sramek, N R Cutler
Journal of Clinical Pharmacology
|
November 15, 2000
Investigator perspective on MTD: practical application of an MTD definition--has it accelerated development?
N R Cutler, J J Sramek
Alzheimer Disease and Associated Disorders
|
July 3, 1998
Guidelines for conducting bridging studies in Alzheimer disease
N R Cutler, J J Sramek
European Journal of Clinical Pharmacology
|
January 1, 1995
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study
N R Cutler, J J Sramek
Drug Intelligence & Clinical Pharmacy
|
March 1, 1981
Psychotic exacerbation with haloperidol
F L Tornatore, D Lee, J J Sramek
Drug Intelligence & Clinical Pharmacy
|
May 1, 1988
Neuroleptic plasma concentrations and clinical response: in search of a therapeutic window
J J Sramek, S G Potkin, R Hahn
Drug Intelligence & Clinical Pharmacy
|
April 1, 1987
Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia
J M Herrera, J J Sramek, J F Costa
The American Journal of Psychiatry
|
April 1, 1986
Neuroleptic dosage for Asians: a failure to replicate
J J Sramek, M A Sayles, G M Simpson
Expert Opinion on Investigational Drugs
|
April 3, 2001
The status of ongoing trials for mild cognitive impairment
J J Sramek, A E Veroff, N R Cutler
Archives of Neurology
|
September 1, 1993
Poor tolerability of MK-458
N R Cutler, J J Sramek, G A Block
Page
of 11
Search research articles
Search
Showing results (11-20 of 105) with videos related to
Sort By:
Page
of 11
The New England Journal of Medicine
|
January 5, 1995
The use of placebo controls
J J Sramek, N R Cutler
Journal of Clinical Pharmacology
|
November 15, 2000
Investigator perspective on MTD: practical application of an MTD definition--has it accelerated development?
N R Cutler, J J Sramek
Alzheimer Disease and Associated Disorders
|
July 3, 1998
Guidelines for conducting bridging studies in Alzheimer disease
N R Cutler, J J Sramek
European Journal of Clinical Pharmacology
|
January 1, 1995
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study
N R Cutler, J J Sramek
Drug Intelligence & Clinical Pharmacy
|
March 1, 1981
Psychotic exacerbation with haloperidol
F L Tornatore, D Lee, J J Sramek
Drug Intelligence & Clinical Pharmacy
|
May 1, 1988
Neuroleptic plasma concentrations and clinical response: in search of a therapeutic window
J J Sramek, S G Potkin, R Hahn
Drug Intelligence & Clinical Pharmacy
|
April 1, 1987
Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia
J M Herrera, J J Sramek, J F Costa
The American Journal of Psychiatry
|
April 1, 1986
Neuroleptic dosage for Asians: a failure to replicate
J J Sramek, M A Sayles, G M Simpson
Expert Opinion on Investigational Drugs
|
April 3, 2001
The status of ongoing trials for mild cognitive impairment
J J Sramek, A E Veroff, N R Cutler
Archives of Neurology
|
September 1, 1993
Poor tolerability of MK-458
N R Cutler, J J Sramek, G A Block
Page
of 11